Biomerica Reports Fiscal 2026 Year-End Financial Results
Rhea-AI Summary
Biomerica (NASDAQ: BMRA) reported fiscal 2026 revenue of approximately $4.50 million versus $5.30 million in 2025, with gross margin near 8%. Net loss improved about 24% to $3.8 million, or $(1.30) per share, aided by $1.1 million Employee Retention Credit income and a $335,000 unrealized gain on its Diagnosis S.A. investment.
Fourth-quarter 2026 net sales rose roughly 17% year over year to $875,000, while quarterly net loss narrowed 27% to about $1.1 million. R&D expense declined 23% to $788,000 as inFoods IBS and hp+detect transitioned toward commercialization, though total operating expenses were steady at around $5.7 million.
Biomerica highlighted inFoods IBS reimbursement progress, with 100% of initial valid Medicare claims paid at the full $300 CMS rate, strong real-world IBS symptom reduction data, a $1.75 million CDMO development agreement, first commercial orders for its hp+detect H. pylori test in Europe, and launch of an AI-backed dietary support tool. Post year-end, the company raised $2.23 million in equity and engaged B. Riley Securities to advise on potential strategic transactions.
Positive
- Q4 2026 net sales approximately $875,000, up about 17% year over year
- Full-year net loss improved ~24% to $3.8 million, loss per share $(1.30)
- Operating cash use fell ~11% to $3.42 million in fiscal 2026
- R&D expenses decreased ~23% to $788,000 as programs moved toward commercialization
- $1.75 million CDMO Master Services Agreement expected to use existing infrastructure with minimal incremental costs
- 100% of valid Medicare claims for inFoods IBS paid at $300 CMS rate to date
- $2.23 million post-year-end equity financing at $1.60 per share with no warrants or discounts
Negative
- Fiscal 2026 revenue declined to $4.50 million from $5.30 million year over year
- Gross profit decreased to about $362,000, with low gross margin around 8%
- Operating loss widened slightly to approximately $5.3 million from $5.1 million
- Year-end cash fell to about $1.3 million from $2.4 million before subsequent financing
- Improved net loss relied partly on $1.1 million Employee Retention Credit and a $335,000 unrealized gain
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 13 | Q3 earnings report | Negative | +1.0% | Lower quarterly sales accompanied commercialization and cost-control updates. |
| Jan 14 | Q2 earnings report | Negative | -0.6% | Revenue declined despite improved working capital, cash, and reduced R&D spending. |
| Oct 15 | Q1 earnings report | Positive | -0.7% | Margins and operating expenses improved, supported by a non-recurring tax credit. |
| Apr 15 | Q3 earnings report | Positive | +3.1% | Revenue growth, margin expansion, expense reductions, and regulatory progress were reported. |
| Jan 15 | Q2 earnings report | Positive | +6.8% | Revenue growth, margin expansion, cost savings, and reduced operating losses were reported. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings reactions were mixed, with three aligned events and two divergences across the five historical results.
Key Terms
cdmo technical
ivd technical
p-value medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Fiscal 2026 fourth quarter net sales increased approximately
17% compared to the fourth quarter of fiscal 2025 - Full-year net loss improved by approximately
24% to approximately$3.8 million - InFoods IBS update:
100% of all initial valid claims processed to date have been paid at the full CMS payment rate of$300 - Research and development expenses decreased
23% as key programs transition toward commercialization - Subsequent to fiscal year-end: completed a
$2.23 million financing with no warrants or discounted securities, including participation from B. Riley Principal Capital, B. Riley executives and all members of the board of directors - Engaged B. Riley Securities, Inc. to support the Board's ongoing evaluation of potential Strategic Opportunities, Including Partnerships and Business Combinations
IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2026 (“Fiscal 2026”).
Business Highlights
InFoods® IBS Medicare Claims Update: Biomerica and its laboratory partner have been submitting initial Medicare claims for inFoods® IBS. The Company noted that
First Commercial Order for H. pylori Test: Biomerica received its first commercial order for hp+detect™ from one of the largest clinical laboratory chains operating across Europe, and subsequently received several reorders. The Company also has evaluations of the test with additional prospective laboratories which are part of one of the largest lab chains in Europe.
InFoods® IBS Real-World Data: Nearly
Reimbursement Infrastructure for inFoods® IBS Established: During fiscal 2026, the American Medical Association CPT Editorial Panel issued a dedicated CPT® Proprietary Laboratory Analyses (PLA) code for inFoods® IBS; the Centers for Medicare and Medicaid Services (CMS) established a national Medicare payment rate of
AI-Backed inFoods® IBS Trigger Food Navigator Launched: Biomerica launched a comprehensive AI-backed digital companion tool designed to better enable patient dietary compliance and improve treatment success for individuals with Irritable Bowel Syndrome (IBS). The new AI-backed Trigger Food Navigator builds on this therapeutic technology by making it easier for patients to follow their personalized dietary plan through smart meal suggestions, ingredient substitutions, and simplified meal planning tools (www.infoodsibs.com).
Q4 and Full-Year Fiscal 2026 Financial Results
For the fourth quarter of Fiscal 2026, net sales were approximately
Net sales for Fiscal 2026 were approximately
Gross profit for Fiscal 2026 was approximately
Biomerica continued to focus resources on key commercial opportunities while maintaining disciplined expense management. Total operating expenses were approximately
Net cash used in operating activities decreased approximately
Net loss improved approximately
As of May 31, 2026, Biomerica had approximately
Subsequent to fiscal year-end, in August 2026, the Company completed a private placement of approximately 1.39 million shares of common stock at a purchase price of
| Selected Financial Results | Year Ended May 31, | Year Ended May 31, | |||||||
| 2026 | 2025 | ||||||||
| ($ in millions, except percentages) | |||||||||
| Revenue | $4.50 | $5.30 | |||||||
| Gross magin | 8% | 9% | |||||||
| Operating expenses | $5.70 | $5.60 | |||||||
| Operating loss | ( | ) | ( | ) | |||||
| Net Loss | ( | ) | ( | ) | |||||
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development. The Company's Board of Directors continues to evaluate potential strategic opportunities with the goal of maximizing long-term shareholder value.
About inFoods® IBS
The inFoods® IBS test involves a simple blood collection procedure and is designed to assess a patient’s above normal immunoreactivity to specific foods. Instead of difficult-to-manage broad dietary restrictions, physicians can now use the inFoods® IBS information to make targeted, patient-specific recommendations about specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. Further information about Biomerica’s patented inFoods® Technology Platform can be found at: https://biomerica.com/inFoods/our-technology/. The inFoods® IBS clinical study was performed at several prominent centers including Mayo Clinic, Beth Israel Deaconess Medical Center Inc. - a Harvard Medical School Teaching Hospital, Houston Methodist Hospital, and the University of Michigan. The clinical results for the Abdominal Pain Intensity (API) responder endpoint of >
For more information about inFoods® IBS, visit www.inFoodsibs.com.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release contains statements that are forward-looking, such as statements relating to the Company’s current and future cash position, balance sheet, cost savings, sales, revenues, overhead, expenses, cost of goods, operations, and earnings; the Company's need for raising additional capital; the Company's expected sales growth for the Company's inFoods® IBS product, hp+detect™ product, CDMO offerings and other existing products; and diversification of the Company's revenue streams. Such forward-looking information is based upon the current beliefs and expectations of management and involves important risks and uncertainties that could significantly affect anticipated results. Such important risks and uncertainties include, among others: earnings and other financial results; results of studies testing the efficacy of the Company’s inFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company’s products; availability of the Company’s test kits and other products; capacity, shipping logistics, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulatory compliance and oversight, and the Company’s ability to obtain patent protection on any aspects of its diagnostic or therapeutic technologies; fluctuations in the Company's operating results due to its business model and expansion plans; downturns in international and/or national economies; the Company’s ability to raise additional capital; the competitive environment in which the Company will be competing; and the Company's dependence on strategic relationships. Additional factors that could cause actual results to differ from those expressed in the forward-looking statements are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the U.S. Securities and Exchange Commission (the “SEC”), and available on the SEC's website (www.sec.gov). In addition, these forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica.
The Company is under no obligation to update any forward-looking statements after the date of this release.
Corporate Contact:
Zack Irani
949-645-2111
investors@biomerica.com
Source: Biomerica, Inc.
